Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (June 2025)
26 slides from Island Pharmaceuticals's investor presentation, Jun 17, 2025
Slide 1: ASX Announcement: Successful Phase 2 PROTECT trial top-line results
17 June 2025 ASX Announcement Successful Phase 2 PROTECT trial top-line results: Webinar presentation • Presentation summarises highly encouraging phase 2a/b top-line results that advocate for the continued clinical development of ISLA-101 in dengue virus • ISLA-101 delivered a meaningful reduction
Slide 2: About Island Pharmaceuticals and contacts
- Ends - To subscribe to Island’s monthly newsletter, IslandWatch, and other forms of email communications, please visit this page of our website. Approved for release to the ASX by: David Foster (CEO and Managing Director) Island Pharmaceuticals Limited info@islandpharmaceuticals.com Investors and
Slide 3: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS DR DAVID FOSTER, MANAGING DIRECTOR June 2025 (ASX: ILA) ISLAND PHARMACEUTICALS 1 June 2025
Slide 4: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financia
Slide 5: For personal use only
For personal use only Dengue infects up Major market to 400m per year* potential Island Pharmaceuticals (ASX: ILA) is an antiviral therapeutics company Positive results in Phase 2a/b PROTECT clinical targeting infectious diseases aggressive models trial in dengue completed PRV potential Pipeline exp
Slide 6: Corporate Overview
CORPORATE OVERVIEW Snapshot Price & volume (12 month) For personal use only Share on issue1: 236,093,034 10 Volume 0.30 Share price 0.25 8 Price per share1: $0.165 0.20 6 $38.96m Market capitalisation1: 0.15 Daily Volume (Millions) Price ($) 4 0.10 Cash at bank (31 March 2024)2: $4.82m 2 0.05 May 20
Slide 7: Benefits of Drug Repurposing
BENEFITS OF DRUG REPURPOSING For personal use only ILA is well advanced in its clinical development pipeline ISLAND PHARMACEUTICALS 5 June 2025
Slide 8: Increased Likelihood of Success
INCREASED LIKELIHOOD OF SUCCESS For personal use only Probability of successful Phase III transition Drug Development - Overall probability of post phase II) for infectious disease success treatments increases to 64% Hematology 17.8% Infectious Disease 15.5% • Treatments for infectious disease have
Slide 9: Dengue - Common and Spreading
DENGUE - COMMON AND SPREADING For personal use only US$8.9B Estimated impact to the HealthMap: recent reports of local or imported dengue cases (March 2025) economy from dengue fever “About half of the world's population is now at risk of dengue with an estimated 100 – 400 million infections occurri
Slide 10: A Multi-Billion-Dollar Market Opportunity
A MULTI-BILLION-DOLLAR MARKET OPPORTUNITY For personal use only Dengue Fever treatment – Growth forecast (USD Bn) 4.00 $3.67 $3.47 3.50 $3.29 $3.12 • Currently no specific small molecule targeting dengue – $2.96 providing ILA with the opportunity to be first to market $2.80 Market Size - USD (Bn) 3.
Slide 11: ISLA-101 - Broad Activity Evident
ISLA-101 – BROAD ACTIVITY EVIDENT For personal use only Demonstrated activity against flaviviruses (subgroup of arboviruses) in models of infection • ISLA-101 has demonstrated broad anti-viral activity in in-vitro models • Demonstrated potent anti dengue-1 activity in in-vitro models using fresh Den
Slide 12: Preventing Animal Deaths from Lethal Dengue and Protective Against Zika
PREVENTING ANIMAL DEATHS FROM LETHAL DENGUE AND PROTECTIVE AGAINST ZIKA For personal use only Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISLAND PHARMACEUTICALS 10 June 2025
Slide 13: Phase 2a/b (PROTECT) Study Overview
PHASE 2A/B (PROTECT) STUDY OVERVIEW For personal use only Study aim was to determine a path forward for ISLA-101 – Results indicate clear signals of drug effect, highlighting success Randomised, double blind, placebo-controlled dengue challenge study – prophylactic and treatment challenge: • Study i
Slide 14: Phase 2a/b (PROTECT) Design
PHASE 2A/B (PROTECT) DESIGN For personal use only Phase 2A: Preventative cohort Administer ISLA-101 daily • Phase 1 (completed April 2024) achieved all study outcomes relating to safety and dosing, demonstrating benefit of Challenge study approach • Phase 2a subjects dosed in October 2024 20 28 45 9
Slide 15: Prototypical Dengue Challenge Infection
PROTOTYPICAL DENGUE CHALLENGE INFECTION For personal use only Endy et al, J Inf Dis 2021 ISLAND PHARMACEUTICALS 13 June 2025
Slide 16: Island's 'PROTECT' Strategy
ISLAND’S ‘PROTECT’ STRATEGY For personal use only Prophylactic- dose before infection Treatment- dose 7 days post infection - some subjects are symptomatic and viremic ISLAND PHARMACEUTICALS 14 June 2025
Slide 17: PROTECT Initiative - Go or No-Go
PROTECT INITIATIVE – GO OR NO-GO For personal use only Study goal was to investigate if ISLA-101 shows activity against dengue in humans. If yes, ILA can proceed with the program. If not, the program would not proceed. Preventative Therapeutic Decision Positive Negative GO Negative Positive GO Posit
Slide 18: Positive Phase 2a/b Top-Line Results
POSITIVE BENEFITSPHASE OF DRUG 2A/B For personal use only REPURPOSING TOP-LINE RESULTS: - Highly encouraging top-line results advocate for the ongoing clinical development of ISLA-101 in dengue - ISLA-101 associated with meaningful reduction in viremia (viral load) and symptoms in preventative cohor
Slide 19: Duration of Viral Load - RNAemia
DURATION OF VIRAL LOAD- RNAEMIA For personal use only ISLA-101 treated subjects exhibited shorter exposure to virus • Control subjects had detectable viral RNA for ~10.5 days • Both treatment and preventative cohorts exhibited detectable viral RNA for ~8.5 days – two days shorter than control ISLAND
Slide 20: Evidence of Anti-Dengue Activity
EVIDENCE OF ANTI-DENGUE ACTIVITY For personal use only • Using two measures of viral load, a clear reduction in viral load was witnessed in the preventative arm and trend towards viral load reduction in the treatment arm • Mean peak virus level (RNA) detected – 13,000,000 units in control and ~73,00
Slide 21: Evidence of Reduced Viral Load
EVIDENCE OF REDUCED VIRAL LOAD For personal use only *Lowest ISLA-101 blood concentration Peak viral load reduced in ISLA-101 treated subjects • Viral RNA substantially reduced in preventative arm compared to internal control (blue) and historical controls (J9 in grey) • Mean virus level decreased f
Slide 22: Summary of Signs/Symptoms
SUMMARY OF SIGNS/SYMPTOMS For personal use only Reported symptoms 1 1: Control- 21/33 reported symptoms (63.6%) 2: Prophylaxis- 11/33 reported symptoms (33.3%) 0.5 3: Delayed treatment- 54/88 reported symptoms (61.4%) 0 1 2 3 ISLAND PHARMACEUTICALS 20 June 2025
Slide 23: Select Symptoms and Lab Abnormalities
SELECT SYMPTOMS AND LAB ABNORMALITIES For personal use only ISLAND PHARMACEUTICALS 21 June 2025
Slide 24: Key Findings and Next Steps
KEY FINDINGS AND NEXT STEPS For personal use only Top-line results demonstrate clear positive signal and provide evidence of activity in humans, answering the first study inquiry with a resounding signal to proceed with program. Results from both arms are encouraging and advocate for additional clin
Slide 25: Potential Trial and Regulatory Pathways
POTENTIAL TRIAL AND REGULATORY PATHWAYS For personal use only Defined clinical and regulatory route based on Phase 2a/b study results • Two potential pathways based on further investigation of Phase 2a/b results • Discussions advancing with multiple potential strategic partners for additional phase
Slide 26: Island Pharmaceuticals
For personal use only Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 24 June 2025
Island Pharmaceuticals — Investor Presentation (June 2025) on 6ix